Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Auditor change
Inhibitor Therapeutics, Inc. (HPPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2022 8-K Quarterly results
09/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Notice of Pendency of Derivative and Class Actions, Proposed Settlement and Settlement Hearing",
"Notice of Pendency of Derivative and Class Actions, Proposed Settlement and Settlement Hearing"
06/03/2022 8-K Quarterly results
01/18/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Letter Agreement to Amend Term Debt Facility, between the Company and Mayne Pharma"
01/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/17/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lender: Mayne Pharma Ventures Pty Ltd or its nominated affiliate Borrower: Inhibitor Therapeutics, Inc. Structure: Term Debt Facility Line Amount: USD231,000 Availability: USD81,000 in the first annual quarter of the term starting 14 December 2020 and USD75,000 in each of the subsequent second and third annual quarters, unless Mayne Pharma, acting in its sole and absolute discretion, gives notice to INTI at least 30 days before the start of a quarter that it is discontinuing funding and that INTI will not be able to draw down additional funds. 1 Purpose: General working capital and corporate purposes as the Board of INTI considers appropriate to meet its legal and regulatory requirements, payment of the outstanding accounts payable and the transaction costs listed on Schedule 1 hereto, and..."
09/23/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
06/08/2020 8-K Other Events
05/06/2020 8-K Quarterly results
04/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/03/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/27/2019 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement
08/20/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial S...
Docs: "Certificate of Amendment to the Company's Certificate of Incorporation",
"HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to “INTI” Effective August 20, 2019",
"Company corporate presentation"
07/17/2019 8-K Regulation FD Disclosure, Other Events
07/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/19/2019 8-K Other Events
04/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals Tampa, FL, April 15, 2019 - HedgePath Pharmaceuticals, Inc. , a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders, announced today that HedgePath's Board of Directors has elected W. Mark Watson, CPA as Chairman of the Board, effective April 15, 2019. As previously announced, E. Brendan Magrab, HedgePath's Chairman of the Board since December 2016, is stepping down from that position in order to fulfill his duties as Chief Executive Officer of Epalex Corporation, a privately-held biotechnology company. Mr. Magrab is expected to continue to serve on the HedgePath board until the ..."
02/13/2019 8-K Quarterly results
12/31/2018 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Employment Letter Agreement, between the Company and Nicholas J. Virca",
"Employment Letter Agreement, between the Company and Garrison J. Hasara"
12/17/2018 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements"
11/05/2018 8-K Regulation FD Disclosure
07/10/2018 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
Docs: "HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing"
01/11/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Certificate of Designation of Series B Preferred Stock of the Company",
"Certificate of Correction to the Certificate of Designation of Series B Preferred Stock of the Company",
"Form of Warrant",
"Securities Purchase Agreement, between the Company and Mayne Pharma",
"Amendment No. 2 to Second Amended and Restated Supply and License Agreement and Amendment No. 1 to Sublicense Agreement, by and among Mayne Pharma, Mayne Pharma International and the Company.(*)",
"HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs"
12/20/2017 8-K Submission of Matters to a Vote of Security Holders
10/05/2017 8-K Quarterly results
07/27/2017 8-K Form 8-K - Current report:
05/30/2017 8-K Form 8-K - Current report
01/24/2017 8-K Form 8-K - Current report
12/02/2016 8-K Form 8-K - Current report
11/28/2016 8-K Form 8-K - Current report
11/08/2016 8-K Changes in Control of Registrant
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy